Mentioned in ?
References in periodicals archive ?
InSite Vision is advancing two product candidates that utilize low-concentrations of bromfenac enabled by DuraSite.
075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY([TM])/Xibrom (bromfenac ophthalmic solution) 0.
Without limiting the foregoing, but by way of example, statements contained in this press release relating to ISTA's 2010 expected financial results, ISTA's expectation to begin a Phase 3 study for ISTA's new formulation of bromfenac in 2010 and complete the formulation of bepotastine nasal and initiate full-scale clinical development during the year are forward-looking statements.
In addition, we are evaluating a new formulation and lower concentrations of bromfenac called REMURA(TM) for the potential treatment of dry eye which is now in Phase 3 clinical studies.
These results were presented in poster sessions at the 6th International Conference on the Tear Film & Ocular Surface in Florence, Italy, in poster presentations titled "Bromfenac Ophthalmic Solution for Treating the Signs of Dry Eye Disease" and "Alleviation of Dry Eye Disease Symptoms with Bromfenac Ophthalmic Solution.
We also made progress toward our Phase 3 lower concentration bromfenac dry eye study, an additional product candidate in our Xibrom family of anti-inflammatory eye care products.
In addition to XiDay, the Company's pipeline includes a bromfenac formulation for dry eye and a bepotastine formulation for nasal allergy.
ISV-101 is being developed to treat dry eye disease, and combines a low dose of bromfenac with the DuraSite technology.
Study results showed that the mean concentration of bromfenac in the aqueous humor of patients in BromSite's group was more than twice greater compared to those patients in Bromday's group with a P-Value of p=0.
Included in the year-end cash balance estimate is $20 million to $25 million in reserved bromfenac royalties.
ophthalmic rights to bromfenac in May 2002 under a license from Senju Pharmaceuticals Co.